Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference
27 Febrero 2024 - 6:00AM
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology
company developing novel, investigational engineered cytokine
therapies designed to address areas of unmet need for patients with
a variety of cancers, today announced that CEO Caroline Loew, Ph.D.
will present at the TD Cowen 44th Annual Health Care Conference on
March 5th at 10:30am ET. A live webcast of the presentation will be
available at ir.muraloncology.com/events-and-presentations. A
replay of the webcast will be archived and available following the
event.
About Mural OncologyMural Oncology is
leveraging its novel protein engineering platform to develop
cytokine-based immunotherapies for the treatment of cancer. By
combining our expertise in cytokine biology and immune cell
modulation and our protein engineering platform, we are developing
medicines to deliver meaningful and clinical benefits to people
living with cancer. Our mission is to broaden the potential
and reach of cytokine-based immunotherapies to improve the lives of
patients. Our lead candidate, nemvaleukin, is currently in
potentially registrational trials in mucosal melanoma and
platinum-resistant ovarian cancer. Mural Oncology has its
registered office in Dublin, Ireland, and its primary facilities in
Waltham, Mass. For more information, visit Mural Oncology’s website
at www.muraloncology.com and follow us on LinkedIn and X.
Contacts
Investors:David Borah,
CFAdavid.borah@muraloncology.com
Media:Katie
Sullivankatie.sullivan@muraloncology.com
Mural Oncology (NASDAQ:MURA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Mural Oncology (NASDAQ:MURA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024